Evidence map›Paper›PMID 24593672›Full record

ArticleStem cells and development2014

Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model.

Te Liu, Yongyi Huang, Jian Zhang, Wenxing Qin, Huiying Chi, Jiulin Chen, Zhihua Yu, Chuan Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells and development, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Human Wharton's Jelly Mesenchymal Stem Cells Improve Insulin Levels and Reduce Weight Gain in Aging Female Rats.International journal of hematology-oncology and stem cell research · 2026
    Article
  4. Review
  5. Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Regenerative therapies for refractory thin endometrium inFrontiers in cell and developmental biology · 2025
    Review
  11. HuMenSCs Initiate the Uterus Stromal Decidualization in Mouse.Current stem cell research & therapy · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Te Liu1 Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine , Shanghai, China .
Yongyi Huang
Jian Zhang
Wenxing Qin
Huiying Chi
Jiulin Chen
Zhihua Yu
Chuan Chen
Shanghai University of Traditional Chinese Medicine · CNSecond Military Medical University · CNShanghai Jiao Tong University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of premature ovarian failure (POF), also known as ovarian insufficiency, has been increasing in recent years. Although some treatments are currently available, improved treatment strategies are urgently required. Many researchers have reported that human endometrial stem cells (HuMenSCs), which exhibit stem/progenitor cell properties in vitro repaired damaged cells in vivo. Thus, we aimed to determine whether HuMenSCs can serve as cell therapy tools and be used for the treatment of POF. After treating with cyclophosphamide, on the first estrus period (we predicted mouse estrus cycle was generally 5 days), HuMenSCs were injected into a cyclophosphamide-induced mouse model of POF. The results revealed that the HuMenSCs could survive within POF mouse ovaries for at least 14 days in vivo; further, ovaries of the HuMenSCs-transplanted group expressed higher levels of ovarian markers [AMH, inhibin α/β, and follicle-stimulating hormone receptor (FSHR)], and the proliferative marker Ki67. In addition, the ovarian weight, plasma E2 level, and the number of normal follicles increased over time in the HuMenSC group compared with the control group. Further, microarray analysis of cDNA expression patterns revealed that, after HuMenSC transplantation, the gene mRNA expression patterns in the ovarian cells following stimulation of the host ovarian niche became increasingly similar to those observed in human ovarian tissue compared with the pretransplantation mRNA expression pattern in HuMenSCs. Hence, we can safely conclude that the mesenchymal stem cell properties and in vivo survival of HuMenSCs make them ideal seed cells for stem cell transplantation in the treatment of POF.

Indexed as

Stem Cell TransplantationAnimalsBiomarkersCells, CulturedCell SurvivalDisease Models, AnimalFemaleHumansMenstruationMesenchymal Stem CellsMice, Inbred C57BLOrgan SizeOvaryPrimary Ovarian InsufficiencyTranscriptomeBiomarkers

Identifiers

PMID24593672
PMCPMC4066227
OpenAlexW2036386857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.